scholarly article | Q13442814 |
P2093 | author name string | Y Liu | |
J M Siegfried | |||
C L Thomas | |||
S Dacic | |||
S A Belinsky | |||
J H Schiller | |||
A M Bernauer | |||
C M Yingling | |||
D M Klinge | |||
M Tessema | |||
S E Dahlberg | |||
P2860 | cites work | Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans | Q24309373 |
HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. | Q24541580 | ||
Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer | Q24550887 | ||
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma | Q24651026 | ||
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
Phase II study of oral topotecan in advanced non-small cell lung cancer | Q28374804 | ||
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer | Q28384157 | ||
Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers | Q28389551 | ||
Heparan sulphate proteoglycans fine-tune mammalian physiology | Q29619329 | ||
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study | Q30434661 | ||
Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells | Q33282863 | ||
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer | Q33331774 | ||
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer | Q33371137 | ||
Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis | Q34134446 | ||
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins | Q34377284 | ||
High-affinity binding of interferon-gamma to a basement membrane complex (matrigel). | Q35819475 | ||
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. | Q36882732 | ||
ISG15 as a novel tumor biomarker for drug sensitivity. | Q36922901 | ||
Recent advances with topotecan in the treatment of lung cancer | Q36982314 | ||
6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture | Q38293479 | ||
The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation | Q39665301 | ||
Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis | Q39783590 | ||
A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. | Q39976570 | ||
Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. | Q40002585 | ||
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels | Q40200929 | ||
Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. | Q40536091 | ||
Highly sensitive sequencing of the sulfated domains of heparan sulfate. | Q42814375 | ||
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer | Q46487403 | ||
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. | Q51565999 | ||
Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. | Q53350223 | ||
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. | Q54061091 | ||
Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. | Q55471506 | ||
P433 | issue | 37 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lung cancer | Q47912 |
P304 | page(s) | 4107-4116 | |
P577 | publication date | 2011-12-12 | |
P1433 | published in | Oncogene | Q1568657 |
P1476 | title | SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. | |
P478 | volume | 31 |
Q36803539 | A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer |
Q47719159 | ANK1 Methylation regulates expression of MicroRNA-486-5p and discriminates lung tumors by histology and smoking status |
Q55405721 | Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma. |
Q61447511 | Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells |
Q60044603 | Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer |
Q92890031 | CPSF3 is a promising prognostic biomarker and predicts recurrence of non-small cell lung cancer |
Q28304465 | Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer |
Q38040319 | DNA methylation profiling in the clinic: applications and challenges |
Q21134689 | Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers |
Q39411671 | Epigenetic Regulation of the Biosynthesis & Enzymatic Modification of Heparan Sulfate Proteoglycans: Implications for Tumorigenesis and Cancer Biomarkers |
Q35880987 | Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer |
Q50918830 | Epithelial Deletion of Sulf2 Exacerbates Bleomycin-Induced Lung Injury, Inflammation, and Mortality. |
Q34044005 | GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer |
Q33947935 | Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers |
Q38366332 | Glycosylation alterations in lung and brain cancer |
Q34216446 | HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer |
Q36411445 | ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma |
Q37485675 | Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion |
Q88739656 | Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model |
Q90705574 | Knockdown of interferon-stimulated gene 15 affects the sensitivity of hepatocellular carcinoma cells to norcantharidin |
Q38808822 | Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells |
Q36328370 | Lung cancer: Biology and treatment options |
Q33408836 | Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer |
Q35925048 | SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer |
Q36496211 | SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study |
Q28534127 | SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen |
Q34155300 | Salinity-induced anti-angiogenesis activities and structural changes of the polysaccharides from cultured Cordyceps Militaris |